Polygenic Risk Scores vs Pharmacogenomics: Which One Actually Changes a Prescription?

Both polygenic risk scores (PRS) and pharmacogenomics (PGx) use your DNA to generate health information. But they answer fundamentally different questions, rely on different types of evidence, and produce different types of output. Understanding that distinction matters — especially if you are evaluating genetic health tools and trying to decide which one is relevant to you.

This article explains what each approach does, where each is useful, where each has limitations, and how they differ in evidence standard, clinical actionability, and practical output.

What Are Polygenic Risk Scores?

A polygenic risk score estimates your genetic predisposition to a complex disease — conditions like type 2 diabetes, coronary artery disease, breast cancer, or Alzheimer's disease — by aggregating the effects of thousands to millions of genetic variants.

Each individual variant in a PRS contributes a very small effect. No single variant causes the condition. Instead, the score sums all of these small contributions into a single number, typically expressed as a percentile relative to a reference population. A person in the 95th percentile has a higher genetic predisposition than 95% of the reference group — but this does not mean they will develop the condition, nor does a low score guarantee they will not.

PRS calculations typically rely on data from genome-wide association studies (GWAS), which identify statistical associations between variants and disease outcomes across large populations. Many PRS tools also use imputation — a statistical method that infers unmeasured variants from nearby measured ones using a reference panel — to expand the number of variants included in the score.

Where PRS Is Useful

Polygenic risk scores have genuine and growing applications in genomics:

• Population-level risk stratification. PRS can identify groups at higher genetic risk for complex diseases, which may inform earlier or more frequent screening — for example, recommending earlier mammography for individuals in the top percentile of breast cancer PRS.
• Research and clinical trials. PRS is widely used to stratify study populations by genetic risk, helping researchers design more targeted clinical trials and identify high-risk cohorts.
• Preventive motivation. For some individuals, seeing an elevated risk score can prompt lifestyle changes, dietary adjustments, or conversations with their doctor about screening schedules.
• Complex diseases with no single causal gene. PRS is most informative for conditions where many genes contribute small effects — precisely the conditions where single-gene testing is uninformative.
• Growing clinical pilot programs. Some health systems, including programs associated with the UK Biobank and the NIH All of Us initiative, are evaluating how PRS can be integrated into primary care.

Limitations of Polygenic Risk Scores

• Ancestry sensitivity. Most PRS models are trained on data from European-descent populations. Accuracy decreases significantly for individuals of non-European ancestry, which is a well-documented limitation in the field.
• Probabilistic, not deterministic. A high PRS does not mean you will develop the condition. A low PRS does not mean you are protected. The score reflects relative genetic predisposition, not a diagnosis or prediction.
• Limited clinical actionability today. Most PRS results do not currently change standard-of-care clinical guidelines. A doctor receiving a PRS report may not have a specific clinical pathway to follow based on the score alone.
• Imputed variants are statistical estimates. Imputation fills in variants that were not directly measured on the genotyping array. This is useful when aggregating thousands of variants, but each imputed genotype carries an uncertainty that does not exist for directly genotyped variants.

What Is Pharmacogenomics?

Pharmacogenomics (PGx) is the study of how specific genes affect your response to medications. Unlike PRS, which aggregates thousands of weak effects, pharmacogenomics focuses on a small number of well-characterized genes — called pharmacogenes — where individual variants have a measurable, clinically documented effect on drug metabolism.

The process works like this: your genotype at specific positions is used to determine star alleles, which combine into a diplotype, which maps to a metabolizer phenotype (such as Poor Metabolizer, Intermediate Metabolizer, Normal Metabolizer, or Ultrarapid Metabolizer). That phenotype is then matched to published drug-gene guidelines that recommend specific prescribing adjustments. For a detailed walkthrough, see How Pharmacogenomic Testing Works.

CPIC Guidelines and What “Clinically Actionable” Means

The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes peer-reviewed, evidence-graded guidelines for drug-gene pairs. These guidelines are referenced in clinical pharmacogenomic prescribing decisions at many academic medical centers, health systems, and pharmacy programs. CPIC grades evidence into levels:

• Level A: Strong evidence — genetic information should be used to change prescribing of the affected drug.
• Level B: Moderate evidence — genetic information could be used to change prescribing of the affected drug.
• Level C/D: Limited or insufficient evidence — not included in DecodeMyBio reports.

A finding is “clinically actionable” when a published guideline recommends a specific prescribing change for a specific genotype. For example: CYP2C19 poor metabolizer status leads to a CPIC recommendation to use an alternative to clopidogrel. CYP2C9 and VKORC1 variants lead to specific warfarin dose adjustments. These are not statistical associations — they are specific recommendations tied to specific genotypes. See our methodology page for the full evidence framework.

Why Fewer Genes Can Mean Stronger Evidence

It may seem counterintuitive that analyzing 19 genes could be more clinically useful than analyzing thousands of variants. The distinction is in the type of evidence behind each data point.

In a polygenic risk score, each variant contributes a tiny statistical association identified through GWAS. The individual effect is often too small to act on — the clinical meaning comes only from the aggregate. In pharmacogenomics, each gene included has been studied extensively enough that a single genotype result can change a specific prescribing recommendation. The evidence threshold for inclusion is far higher.

CPIC Level A guidelines require multiple replicated studies, a clear biological mechanism, and sufficient evidence to warrant a change in clinical practice. Genes that do not meet this threshold are excluded — not because they are unimportant, but because the evidence is not yet strong enough to guide a prescribing decision. A smaller gene panel with Level A/B evidence behind every entry produces a report that a prescriber can act on directly. A larger variant set with weaker per-variant evidence produces a probability estimate that requires further clinical context to interpret.

Limitations of Pharmacogenomics

• Limited drug and gene coverage. PGx covers a focused set of genes and medications — not the entire pharmacopeia. Many drugs do not yet have CPIC guidelines.
• Consumer array limitations. Consumer genotyping arrays (23andMe, AncestryDNA) may miss rare alleles and cannot reliably detect structural variants like CYP2D6 gene deletions or duplications.
• Phenoconversion. When one drug inhibits the enzyme that metabolizes another, your effective metabolizer status can change — a phenomenon called phenoconversion. PGx reports based on genotype alone do not account for this.
• Non-genetic factors. Drug response also depends on age, organ function, body weight, diet, and other medications. Genetic information is one input among several.
• Not a diagnostic test. Pharmacogenomic reports support clinical conversations — they do not replace the judgment of a qualified healthcare provider, and they are not a substitute for clinical-grade pharmacogenomic testing when clinical certainty is required.

PRS vs Pharmacogenomics: Side-by-Side Comparison

Imputed Variants vs Directly Genotyped Variants

Imputation is a statistical technique that infers the genotype at positions that were not directly measured on a genotyping array. It works by comparing measured variants to patterns in a reference panel (such as the 1000 Genomes Project) and predicting the most likely genotype at unmeasured positions.

For polygenic risk scores, imputation is a practical necessity. GWAS-identified variants span the entire genome, and no consumer array measures all of them. Since PRS aggregates thousands of small effects, the impact of any single imputation error is diluted across the score. Imputation works well in this context.

For pharmacogenomics, the situation is different. A single variant — such as rs4244285 for CYP2C19*2 — can determine your metabolizer status and drive a specific drug recommendation. Directly genotyping that position provides higher confidence than inferring it from surrounding variants. This is why pharmacogenomic analysis preferentially uses directly measured genotypes from the genotyping array.

Neither approach is inherently better. They are suited to different applications: imputation extends reach when individual precision matters less; direct genotyping provides confidence when individual precision matters more.

When Each Approach Matters

PRS is the right tool when:

• You want to understand long-term disease risk for conditions with no single causal gene.
• You are planning preventive screening — for example, whether to begin earlier monitoring for cardiovascular disease or cancer.
• A doctor is evaluating whether you would benefit from earlier intervention or more frequent testing.
• You are contributing to research or clinical trial stratification.

PGx is the right tool when:

• You are starting a new medication, especially one with CPIC guidance — such as warfarin, clopidogrel, or an SSRI.
• You have experienced unexpected side effects or lack of efficacy with a medication.
• You are in an emergency department and providers need to make a prescribing decision quickly.
• Your psychiatrist is choosing between antidepressants — see pharmacogenomics for depression.
• You are on a drug where dosing is genotype-sensitive, such as warfarin, statins, or thiopurines.

How Consumer DNA Data Fits In

Consumer DNA tests from 23andMe, AncestryDNA, MyHeritage, and FamilyTreeDNA directly genotype hundreds of thousands of variant positions. This raw data includes many of the pharmacogenomic variants needed for PGx analysis — the positions are already measured on the array.

DecodeMyBio extracts the clinically relevant subset from your raw data and maps the results to CPIC guidelines. The output covers 19 genes across three reports: Medication Safety, Nutrition & Methylation, and Psychiatric Medications. Each report includes a clinician pocket summary that a doctor or pharmacist can review in under 60 seconds.

This is not a replacement for clinical-grade pharmacogenomic testing ordered through a healthcare provider. Consumer genotyping arrays have known limitations, including inability to detect structural variants and limited coverage of rare alleles. For situations requiring clinical certainty — such as high-stakes prescribing decisions — a provider-ordered test with CLIA-certified laboratory analysis is appropriate. DecodeMyBio provides an informational starting point using data you already have.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. DecodeMyBio provides informational pharmacogenomic reports — not clinical diagnostic testing. Always consult a qualified healthcare provider before making any medication changes.